

Memo no.: 2026-019
Date: 31-August-2026
Memo to: Clients
Re: ***Acetylcholine Receptor Antibodies by RIPA – Testing Delay and Additional Analysis***

Due to manufacturer issues at the performing laboratory, [Acetylcholine Receptor Antibodies by RIPA, Serum](#) analysis will be delayed through September 2026.

During this delay, [Clustered Acetylcholine Receptor Antibodies by CBA, Serum](#) testing will be performed and reported at no charge for all patients with pending RIPA analysis.

RIPA analysis will later be performed and reported after the manufacturing issue has been resolved.

In the interim, ICL will report the [Clustered Acetylcholine Receptor Antibodies by CBA, Serum](#) with the following report comment to advise of the change:

“Manufacturing issues have delayed Acetylcholine Receptor Antibody by RIPA analysis through September 2026. During this delay, analysis will first be performed (at no charge) using a cell-based assay (reported above); RIPA analysis will be performed and reported after the manufacturing issue has been resolved”.

If you have further questions, please contact Client Care at 416-422-3000 ext. 300 or info@iclabs.ca

Dr. Shashank Tilak, Ph.D., DCC
Laboratory Director
416-422-3000 ext. 221
shashtilak@iclabs.ca